Vertex Presents Data Demonstrating Significant Benefits of L

-Interim results of largest real-world study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction in pulmonary exacerbations frequency and lower rates of lung transplant and death for people with cystic fibrosis-- Twelve presentations add to the body...

Related Keywords

France , Australia , London , City Of , United Kingdom , Austria , Germany , Paris , France General , Boston , Massachusetts , United States , Cambridge , Cambridgeshire , Vienna , Wien , America , German , Isabelle Fajac , European Cystic Fibrosis Society , Companies To Work , European Union , Cystic Fibrosis Foundation Patient Registry , Twitter , Exchange Commission , Linkedin , Instagram , Vertex Pharmaceuticals Incorporated Nasdaq , Vertex Pharmaceuticals Incorporated , Youtube , Facebook , European Cystic Fibrosis Conference , Late Breaking Science , Professor Isabelle Fajac , Cochin Hospital , Assistance Publique H , Paris Cit , About Cystic , Innovation District , North America , Top Employers , Private Securities Litigation Reform Act , Cystic Fibrosis , While Vertex ,